Solid Biosciences (SLDB) Net Income towards Common Stockholders (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$60.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 60.13% year-over-year to -$60.7 million; the trailing twelve-month figure through Mar 2026 stood at -$197.4 million (down 40.29% YoY), and the FY2025 full-year result was -$359.7 million, down 43.35% from the prior year.
• Net Income towards Common Stockholders declined to -$60.7 million in Q1 2026, from -$47.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$20.6 million in Q3 2022 to a low of -$196.6 million in Q4 2022.
• A 5-year average of -$43.4 million and a median of -$32.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 87.45% in 2023 and tumbled 70.15% in 2024, its largest moves.
• Tracing SLDB's Net Income towards Common Stockholders over 5 years: stood at -$196.6 million in 2022, then soared by 87.45% to -$24.7 million in 2023, then plunged by 70.15% to -$42.0 million in 2024, then slipped by 12.83% to -$47.4 million in 2025, then declined by 28.13% to -$60.7 million in 2026.
• Business Quant data shows SLDB's Net Income towards Common Stockholders at -$60.7 million in Q1 2026, -$47.4 million in Q4 2025, and -$47.1 million in Q3 2025.